![PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis](https://d3i71xaburhd42.cloudfront.net/32d1dd0e96918f7d38cc1a05cb6a983573e968e5/15-Table1-1.png "PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis")
PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis
Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51 | Journal of
ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban | tctmd.com
Rivaroxaban in patients with a recent acute coronary syndrome event: i | VHRM
NOACS: Emerging data in ACS/IHD - ppt download
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51 - ScienceDirect
Role of Oral Anticoagulants in Patients After an Acute Coronary Syndrome | Arteriosclerosis, Thrombosis, and Vascular Biology
ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Impact of rivaroxaban on stent thrombosis and secondary prevention of | RRCC
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/4-Figure1-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/5-Figure4-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
ATLAS ACS 2-TIMI 51: Efficacy Endpoints: Very Low-Dose 2.5 mg BID - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library
European Society of Cardiology Chronic Coronary Syndromes Guidelines Review - European Medical Journal
![PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis](https://d3i71xaburhd42.cloudfront.net/32d1dd0e96918f7d38cc1a05cb6a983573e968e5/16-Table2-1.png "PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis")
PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51 | Journal of the American College of Cardiology
Dia 1
